1. A method of avoiding inhibition of myelination by Schwann cells after administration of glial growth factor 2 (GGF2) to a subject, comprising! providing a subject in need of myelination of neurons,! providing GGF2 in a pharmaceutically acceptable carrier,! the introduction of GGF2 to the subject and! determining that the amount of GGF2 is less than the amount that inhibits myelination by Schwann cells. ! 2. The method according to claim 1, in which GGF2 is administered intravenously, intrathecal or topically. ! 3. The method according to claim 1, in which the step of determining includes the introduction of less than the maximum standard value of GGF2. ! 4. The method according to claim 3, in which the maximum standard value of GGF2 is a plasma level of approximately 0.01 nM GGF2. ! 5. The method according to claim 3, in which the maximum normative value of GGF2 is approximately 500 ng GGF2 per kg of body weight. ! 6. The method according to claim 1, wherein the step of determining comprises determining c-Jun levels after the administration step. ! 7. The method according to claim 6, which if the c-Jun levels are increased further comprises the step of administering to the subject a reduced amount of GGF2 relative to the amount initially administered. ! 8. The method of claim 6, wherein c-Jun levels are determined in a fluid selected from the group consisting of intracellular fluid, blood plasma, blood serum, and cerebrospinal fluid. ! 9. The method according to claim 1, wherein the step of determining comprises determining the amount of GGF2 relative to the amount of GGF2, which causes activation of the pathway involving Mek1 / Erk. ! 10. The method according to claim 9, in which the step of determining includes determining that the amount of GGF2 is less than the amount that causes activation of the pathway involving Mek1 / Erk, by detecting phosphoryl1. Способ избегания ингибирования миелинизации шванновскими клетками после введения субъекту фактора 2 роста гл
